株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

タイの医薬品・医療産業(四半期更新レポート)

Thailand Pharmaceuticals and Healthcare Report Q4 2016

発行 BMI Research 商品コード 243374
出版日 ページ情報 英文 102 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
タイの医薬品・医療産業(四半期更新レポート) Thailand Pharmaceuticals and Healthcare Report Q4 2016
出版日: 2016年10月26日 ページ情報: 英文 102 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、タイにおける製薬・医療産業の構造や最新動向について分析し、今後10年間の産業規模の動きを推計すると共に、業界の抱える課題(リスク)や将来的な収益機会(リワード)に関する評価、政府の政策・規制、マクロ経済環境、主要企業のプロファイルといった情報を盛り込んでお届けします。

BMIの見解

SWOT分析

産業予測

  • 医薬品市場の予測
  • 医療市場の予測
  • 処方薬市場の予測
  • 特許薬市場の予測
  • ジェネリック医薬品市場の予測
  • 一般用(OTC)医薬品市場の予測
  • 医薬品の対外貿易状況

産業のリスク/リワード・インデックス

  • アジア太平洋地域:リスク/リワード・インデックス
  • タイ:リスク/リワード・インデックス
    • リワード
    • リスク

規制概要

  • 知的所有権(IP)の問題
  • 価格設定
  • 医療費償還

市場概況

  • 医療部門
  • 研究開発(R&D)部門
  • 治験
  • 疫学

競争環境

  • 研究開発指向型産業
  • ジェネリック医薬品メーカー
  • 医薬品の卸売業
  • 医薬品の小売業

企業プロファイル

  • Berlin Pharmaceutical Industry
  • Biolab
  • GlaxoSmithKline
  • Government Pharmaceutical Organisation
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi

人口構造の予測

用語集

分析手法

  • 医薬品支出額の予測モデル
  • 医療費の予測モデル
  • 分析手法に関する注記
  • リスク/リワード・インデックスの手法
  • インデックスの概要
  • 指標のウェイト付け

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1748-2240

BMI View: Reforms to Thailand's healthcare system will influence the commercial opportunities for multinational drugmakers. While a merger of all three schemes remains difficult, incremental reforms in that direction will be forthcoming and necessary for Thailand to address inequalities in healthcare outcomes. Pressures to ensure the sustainability of the country's healthcare programmes have also not abated. This accentuates the threat of cost containment for drugmakers, which will be heightened should Thailand pursue the target - set by the Committee on Resource Mobilisation for Sustainable Universal Health Coverage - of keeping total health spending less than 5% of GDP by 2022.

Headline Expenditure Projections

  • Pharmaceuticals: THB153bn (USD4.5bn) in 2015 to THB161bn (USD4.6bn) in 2016; +5.3% in local currency terms and +1.9% in US dollar terms.
  • Healthcare: THB841bn (USD24bn) in 2015 to THB892bn (USD25bn) in 2016: +6.1% in local currency and +2.6% in US dollar terms.

Risk/Reward Index

In Q416, Thailand remains in the lower half of the Pharmaceutical Risk/Reward Index table that assesses the attractiveness of 19 countries in the Asia Pacific region, with a score of 49.3 out of 100. While Thailand offers relatively attractive revenue-earning opportunities in a regional-comparison for multinational investors, increasing pharmaceutical expenditure is somewhat overshadowed by the prevalent risks in the country including low levels of patent protection.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Thailand 2014-2020)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • OTC Drug Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Thailand 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q4 2016
  • Thailand Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
  • Pricing Regime
    • Table: Price Build-Up Of Medicines In Thailand
  • Reimbursement Regime

Market Overview

  • Healthcare Sector
    • Table: Major Health Insurance Programmes In Thailand
    • Table: Healthcare Resources (Thailand 2010-2015)
    • Table: Healthcare Personnel (Thailand 2010-2015)
    • Table: Healthcare Activity (Thailand 2010-2015)
  • Research & Development
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In Thailand

Competitive Landscape

  • Research-Based Industry
    • Table: PReMA Members
    • Table: Multinational Market Activity
  • Generic Drugmakers
    • Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector

Company Profile

  • Berlin Pharmaceutical Industry
  • Biolab
  • GlaxoSmithKline
  • Government Pharmaceutical Organisation
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi

Demographic Forecast

  • Table: Population Headline Indicators (Thailand 1990-2025)
  • Table: Key Population Ratios (Thailand 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (Thailand 1990-2025)
  • Table: Population By Age Group (Thailand 1990-2025)
  • Table: Population By Age Group % (Thailand 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top